Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 1 | — | — | 2 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | — | 1 |
Nephritis | D009393 | — | N05 | — | 1 | — | — | — | 1 |
Drug common name | Atrasentan |
INN | atrasentan |
Description | Atrasentan is a member of pyrrolidines. |
Classification | Small molecule |
Drug class | endothelin receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1 |
PDB | — |
CAS-ID | 173937-91-2 |
RxCUI | — |
ChEMBL ID | CHEMBL9194 |
ChEBI ID | — |
PubChem CID | 159594 |
DrugBank | — |
UNII ID | V6D7VK2215 (ChemIDplus, GSRS) |